FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-028									

37 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>van den Broek Richard</u>						2. Issuer Name and Ticker or Trading Symbol Celldex Therapeutics, Inc. [CLDX]										5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last)	(F H STREET	irst)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 12/17/2014											Officer (give title below)			specify	
1ST FLOOR							4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) GREENWICH CT 06830																X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)																		
		Tab	le I - Nor	n-Deriv	ative	Se	curitie	s Ac	cquire	ed, D	isp	osed o	of, or E	Bene	ficiall	y Owned	l				
1. Title of Security (Instr. 3) 2. Trans Date (Month/I					ar)	2A. Deem Executior if any (Month/Da	Co	ransact ode (In		4. Secur Dispose 5)	ities Acq d Of (D)			Benefici Owned I	es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
					Co	ode	v	Amount	ount (A) or (D)		Price	Transac	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)					
Common Stock, par value \$0.001 per share 12/17/						2014				A		2,00	2,000 A		\$0 ⁽¹⁾	2,	,000		D		
		7	able II -									sed of onverti				Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deeme Execution if any (Month/Da	Date,	4. Transa Code (l 8)		of E		Expira	5. Date Exercisal Expiration Date Month/Day/Year			7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	is Silly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerc	isable		epiration ate	Title	or Nu of	Amount or Number of Shares						
Non- Qualified Stock Option (right to buv) ⁽²⁾	\$18.11	12/17/2014			A		8,000		(3	3)	12	1/16/2024	Commo Stock	n 8	3,000	\$0	8,000		D		

Explanation of Responses:

- 1. On December 17, 2014, the Company awarded 2,000 shares of the Company's common stock in the form of restricted stock award under the Celldex Therapeutics, Inc. 2008 Stock Option and Incentive Plan (the "Plan"), subject to time-based forfeiture restrictions.
- 2. Represents an option grant by the Company pursuant to the Plan
- 3. The option becomes exercisable in whole on December 17, 2015

Remarks:

Exhibit 24.1 - Power of Attorney

/s/ Avery W. Catlin, attorney-

12/19/2014

in-fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of Avery W. Catlin and Anthony S. Marucci his true and lawful attorney-in-fact to:

- 1. execute for and on behalf of the undersigned Schedules 13D and 13G, Form ID, and Forms 3, 4 and 5 in accordance with Sections 13 and 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- 2. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Schedules 13D or 13G, Form ID and Forms 3, 4 or 5, and the timely filing of such Forms with the United States Securities and Exchange Commission and any other authority; and
- 3. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, including without limitation the execution and filing of a Form 4 with respect to a transaction which may be reported on a Form 5, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in his discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary and proper to be done in the exercise of any of the rights and powers herein granted, as fully and to all intents and purposes as he might or could do in person, with full power of substitution and resubstitution, hereby ratifying and confirming all that such attorney-in-fact, or his substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming any of the undersigned's responsibilities to comply with Sections 13 and 16 of the Securities Exchange Act of 1934.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 12th day of December, 2014.

<u>/s/ Richard van den Broek</u> Name: Richard van den Broek